Taking together these data highlight the importance of a better understanding on the tissue and disease specificity of these enzymes and suggest that targeting PHD1 and PHD3 for therapeutic purpose in allergic diseases would be more efficient than PHD2. Here, EGLN2 is linked to allergic disease.